Xenon Pharmaceuticals (XENE) Cash & Equivalents (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Cash & Equivalents data on file, last reported at $545.9 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 367.92% year-over-year to $545.9 million in Q1 2026; TTM through Mar 2026 was $545.9 million, a 367.92% increase from a year earlier, with the FY2025 full-year figure at $586.0 million, up 310.64% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $545.9 million, down from $586.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for XENE reached as high as $624.8 million in Q2 2025 and fell as low as $57.2 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $228.5 million across 5 years, with a median of $116.7 million in 2025.
• Across the five-year window, Cash & Equivalents plunged 82.55% in 2023 and soared 533.7% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $57.2 million in 2022, then soared by 159.67% to $148.6 million in 2023, then slipped by 3.99% to $142.7 million in 2024, then jumped by 310.64% to $586.0 million in 2025, then slipped by 6.85% to $545.9 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $545.9 million in Q1 2026, $586.0 million in Q4 2025, and $555.3 million in Q3 2025.